ArticleEndocrine2026
Hemoglobin glycation index and renal progression in patients with type 2 diabetes: a 5-year cohort study.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal progression remains a major unmet clinical challenge in patients with type 2 diabetes mellitus (T2DM). The hemoglobin glycation index (HGI), reflecting inter-individual variability in hemoglobin glycation independent of glucose levels, has been proposed as a complementary glycemic marker; however, its prognostic value for renal outcomes remains uncertain.
methodsWe conducted a prospective cohort study of 441 adults with T2DM followed at a tertiary medical center between 2016 and 2021. HGI was calculated as the difference between observed HbA1c and predicted HbA1c derived from fasting plasma glucose. Baseline and mean first-year HGI and HbA1c were categorized into tertiles. Renal progression was defined as new-onset albuminuria or a ≥ 30% decline in estimated glomerular filtration rate. Associations with renal progression were assessed using Cox proportional hazards models with sequential adjustment for demographic, metabolic, and treatment-related covariates.
resultsDuring a median follow-up of 61 months, 162 participants (36.7%) experienced renal progression. Higher baseline and mean first-year HGI were significantly associated with increased risk of renal progression across most multivariable models. In the fully adjusted model, participants in the highest tertile of mean first-year HGI had a 58% higher risk of renal progression compared with those in the lowest tertile (hazard ratio 1.58, 95% confidence interval 1.01–2.49). Baseline HbA1c was also associated with renal progression. In contrast, associations between HGI and new-onset retinopathy or all-cause mortality were not statistically significant after full adjustment.
conclusionsBoth HGI and HbA1c were independently associated with renal progression in patients with T2DM. These findings suggest that inter-individual variability in hemoglobin glycation may be associated with renal progression in patients with T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.